Posters explore whether HelioLiver™ Dx can flag hepatocellular carcinoma when ultrasound is negative, imaging is indeterminate, or a tumor is not yet visible

海报探讨了HelioLiver™ Dx在超声检查为阴性、影像学结果不确定或肿瘤尚未显现时，是否能够标记出肝细胞癌。

SAN ANTONIO

圣安东尼奥

,

，

Oct. 9, 2026

2026年10月9日

/PRNewswire/ --

/美通社/ --

Helio Genomics

Helio Genomics

today announced four poster presentations at the San Antonio Liver Cancer Symposium (SALCS), October 8–9, evaluating HelioLiver™ Dx in hepatocellular carcinoma (HCC) surveillance.

今日宣布在10月8日至9日举行的圣安东尼奥肝癌研讨会（SALCS）上发布四项海报展示，评估HelioLiver™ Dx在肝细胞癌（HCC）监测中的应用。

The posters include real-world cases showing how HelioLiver may complement conventional imaging by identifying molecular evidence of HCC when ultrasound is negative, imaging is indeterminate, or tumors are not yet radiographically visible. Shivani Mahajan, PhD, Head of Computational Science at Helio Genomics, will present the studies and posters today at SALCS..

这些海报包含真实世界案例，展示HelioLiver如何在超声检查为阴性、影像学结果不确定或肿瘤尚未在影像上可见时，通过识别肝细胞癌（HCC）的分子证据来补充传统影像学检查。Helio Genomics计算科学负责人Shivani Mahajan博士将于今天在SALCS会议上展示这些研究和海报。

Continue Reading

继续阅读

Helio Genomics is an Irvine, Calif.-based cancer diagnostics company working toward a future in which cancer is detected early enough to save lives. The company is building an AI-powered blood surveillance platform for at-risk patients. Its advanced multi-analyte blood-based platform harnesses machine learning and deep learning to detect cancer biomarkers, enabling clinicians and patients to respond decisively against cancer..

Helio Genomics 是一家总部位于加利福尼亚州尔湾的癌症诊断公司，致力于实现一个能够尽早发现癌症以挽救生命的未来。该公司正在为高风险患者构建一个人工智能驱动的血液监测平台。其先进的多分析物血液检测平台利用机器学习和深度学习技术来识别癌症生物标志物，使临床医生和患者能够果断应对癌症。

'One of the most difficult situations in HCC care is an indeterminate imaging finding where the level of clinical concern exceeds what the scan can definitively tell us,' said Hrishikesh Samant, MD, FACG. 'An additional molecular signal may help physicians better distinguish which patients need closer evaluation from those who can continue routine surveillance.'.

“在肝细胞癌（HCC）的诊疗中，最具挑战性的情况之一是影像学检查结果不明确，即临床担忧程度超过了扫描检查所能提供的确定性信息。”美国胃肠病学院院士（FACG）、医学博士 Hrishikesh Samant 表示。“额外的分子信号可能有助于医生更好地区分哪些患者需要更密切的评估，哪些患者可以继续常规监测。”

The four studies highlight:

这四项研究强调：

HCC missed by routine surveillance:

常规监测漏诊的肝细胞癌：

Three cases in which abnormal HelioLiver results prompted additional imaging after ultrasound had not identified a lesion.

三例在超声未发现病灶的情况下，因HelioLiver结果异常而促使进行额外影像学检查的病例。

Resolving tumor ambiguity:

解析肿瘤的不确定性：

Four cases demonstrating potential utility when imaging was indeterminate or definitive imaging was limited, including a biopsy-confirmed HCC following an abnormal HelioLiver result.

四个病例展示了在影像学检查结果不确定或确定性影像学检查受限时，HelioLiver检测的潜在实用价值，其中包括一例在HelioLiver检测结果异常后经活检确诊的肝细胞癌（HCC）病例。

Potential lead-time advantage:

潜在的提前期优势：

Two cases in which abnormal cfDNA methylation signals preceded imaging-visible disease by approximately 6 months, and definitive radiographic HCC diagnosis by as much as 9 months.

两例病例中，异常的cfDNA甲基化信号在影像学可见病灶出现前约6个月即已显现，并在确诊为放射学明确的肝细胞癌（HCC）前多达9个月即已检测到。

Longitudinal surveillance modeling

纵向监测建模

: A simulation study evaluating whether surveillance using HelioLiver could increase detection of tumors while they remain within early-stage treatment criteria compared with ultrasound.

：一项模拟研究，评估与超声检查相比，使用 HelioLiver 进行监测是否能在肿瘤仍处于早期治疗标准范围内时提高其检出率。

'HCC biology begins before a tumor becomes large enough to be clearly visualized on imaging,' said Rahul Maheshwari, MD. 'Detecting tumor-associated molecular changes earlier could give clinicians valuable lead time to identify disease while patients are still within a window for potentially curative treatment.'.

“肝细胞癌（HCC）的生物学变化在肿瘤长到足以在影像学上清晰可见之前就已经开始，”Rahul Maheshwari 医学博士表示。“更早地检测与肿瘤相关的分子变化，可以为临床医生提供宝贵的提前量，使患者在仍处于潜在治愈性治疗窗口期时就能被识别出疾病。”

Together, the findings suggest that tumor-associated molecular changes may provide useful information before or alongside structural changes detected by imaging. HelioLiver Dx integrates cell-free DNA methylation, serum protein biomarkers, and demographic variables to aid early HCC detection.

综上所述，研究结果表明，肿瘤相关的分子变化可能在影像学检测到的结构变化之前或同时提供有用的信息。HelioLiver Dx 整合了无细胞 DNA 甲基化、血清蛋白生物标志物以及人口统计学变量，以辅助早期肝细胞癌（HCC）的检测。

About Helio Genomics

关于 Helio Genomics

Helio Genomics is an Irvine, Calif.-based cancer diagnostics company working toward a future in which cancer is detected early enough to save lives. The company is building an AI-powered blood surveillance platform for at-risk patients. Its advanced multi-analyte blood-based platform harnesses machine learning and deep learning to detect cancer biomarkers, enabling clinicians and patients to respond decisively against cancer..

Helio Genomics 是一家总部位于加利福尼亚州尔湾的癌症诊断公司，致力于实现一个能够尽早发现癌症以挽救生命的未来。该公司正在为高危患者构建一个人工智能驱动的血液监测平台。其先进的多分析物血液检测平台利用机器学习和深度学习技术来检测癌症生物标志物，使临床医生和患者能够对癌症采取果断的应对措施。

About HelioLiver™

关于 HelioLiver™

HelioLiver™, Helio Genomics' lead product, is a blood-based test for early detection of hepatocellular carcinoma (HCC), the most common form of liver cancer. It combines cell-free DNA methylation patterns, protein biomarkers, and patient demographics using a proprietary AI algorithm. In a prospective clinical study it outperformed traditional ultrasound in identifying small tumors in high-risk patients..

HelioLiver™是Helio Genomics公司的旗舰产品，是一种用于早期检测肝细胞癌（HCC，最常见的肝癌类型）的血液检测。它利用专有的人工智能算法，结合无细胞DNA甲基化模式、蛋白质生物标志物和患者人口统计学特征。在一项前瞻性临床研究中，其在识别高危患者的小肿瘤方面优于传统超声检查。

1

1

This simple blood draw addresses screening barriers, boosting early detection rates and improving outcomes for individuals with risk factors for liver cancer, including liver cirrhosis (from hepatitis B, hepatitis C, alcohol, obesity, or MASLD). Clinically validated in multicenter studies involving thousands of patients, Helio Genomics is expanding its commercial footprint to combat this pressing health challenge.

这种简单的抽血检测解决了筛查障碍，提高了早期发现率，并改善了具有肝癌风险因素（包括由乙型肝炎、丙型肝炎、酒精、肥胖或代谢功能障碍相关脂肪性肝病引起的肝硬化）个体的预后。Helio Genomics 已在涉及数千名患者的多中心研究中完成临床验证，目前正扩大其商业布局，以应对这一紧迫的健康挑战。

HelioLiver is a laboratory-developed test..

HelioLiver 是一种实验室开发的检测项目。

Media Contact

媒体联系人

Danielle Fox

丹妮尔·福克斯

360.509.9527

360.509.9527

[email protected]

[email protected]

1

1

A multi-analyte cfDNA-based blood test for early detection of hepatocellular carcinoma. J Hepatol. 2026;85(3):528-536. Published online May 6, 2026. Prospective multicenter CLiMB trial (NCT03694600): HelioLiver sensitivity 47.8% versus 28.3% for abdominal ultrasound; 28.6% versus 0% for lesions smaller than 2 cm.

一种基于多分析物循环游离DNA（cfDNA）的血液检测用于肝细胞癌的早期发现。《肝脏病学杂志》。2026;85(3):528-536。在线发表于2026年5月6日。前瞻性多中心CLiMB试验（NCT03694600）：HelioLiver的敏感性为47.8%，而腹部超声为28.3%；对于小于2厘米的病变，分别为28.6%和0%。

.

。

https://www.journal-of-hepatology.eu/article/S0168-8278

https://www.journal-of-hepatology.eu/article/S0168-8278

(26)00215-1/fulltext

(26)00215-1/全文

SOURCE Helio Genomics

来源：Helio Genomics

21

二十一

%

百分比

more press release views with

更多新闻稿浏览量，通过

Request a Demo

申请演示